Michael J. Tokich
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Morgan Stanley raises Mettler-Toledo price target to $1,575. Morgan Stanley maintained an Equal-Weight rating on Mettler-Toledo while raising its price target to $1,575. This action aligns with the current average analyst target of $1,529.46, which sits below the stock's 52-week high of $1,619.58. The company is also scheduled to host an investor meeting in the near term.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
STERIS (STE) to acquire Xodus Medical for $2.1B. STERIS announced a definitive agreement to acquire Xodus Medical for about $2.1 billion. The deal adds a specialty surgical products business focused on patient and operating‑room staff safety, expanding STE’s consumables portfolio. The acquisition aligns with the company’s strategy to grow its healthcare offerings.
Transaction History
| TFX | ▲ Buy | Grant | 1,090 | $0 | 5/15/2026 | View on chart |
| MTD | ▲ Buy | Grant | 50 | $0 | 2/17/2026 | View on chart |
| STE | ▼ Sell | Tax Withholding | 341 | $83K | 6/4/2025 | View on chart |
| STE | ▲ Buy | Grant | 2,223 | $0 | 6/3/2025 | View on chart |
| STE | ▼ Sell | Tax Withholding | 386 | $93K | 6/2/2025 | View on chart |
| STE | ▼ Sell | Tax Withholding | 172 | $42K | 6/2/2025 | View on chart |
| STE | ▼ Sell | Tax Withholding | 169 | $41K | 6/2/2025 | View on chart |
| STE | ▼ Sell | Tax Withholding | 194 | $46K | 10/1/2024 | View on chart |
| STE | ▼ Sell | Open Market | 427 | $106K | 9/16/2024 | View on chart |
| STE | ▲ Buy | Option Exercise | 20,213 | $2.3M | 9/16/2024 | View on chart |
| STE | ▼ Sell | Open Market | 10,316 | $2.5M | 9/16/2024 | View on chart |
| STE | ▼ Sell | Open Market | 3,485 | $852K | 9/16/2024 | View on chart |
| STE | ▼ Sell | Open Market | 5,985 | $1.5M | 9/16/2024 | View on chart |
| STE | ▲ Buy | Option Exercise | 3,119 | $356K | 9/13/2024 | View on chart |
| STE | ▼ Sell | Open Market | 3,119 | $774K | 9/13/2024 | View on chart |
| STE | ▼ Sell | Open Market | 23,332 | $5.8M | 9/10/2024 | View on chart |
| STE | ▲ Buy | Grant | 23,332 | $2.7M | 9/10/2024 | View on chart |
| STE | ▲ Buy | Grant | 3,423 | $0 | 6/4/2024 | View on chart |
| STE | ▼ Sell | Tax Withholding | 1,100 | $251K | 6/3/2024 | View on chart |
| STE | ▼ Sell | Tax Withholding | 771 | $176K | 6/3/2024 | View on chart |
| STE | ▼ Sell | Tax Withholding | 506 | $116K | 6/3/2024 | View on chart |
| STE | ▼ Sell | Tax Withholding | 580 | $129K | 5/31/2024 | View on chart |
| STE | ▲ Buy | Option Exercise | 32,000 | $2.5M | 5/15/2024 | View on chart |
| STE | ▼ Sell | Open Market | 5,039 | $1.2M | 5/15/2024 | View on chart |
| STE | ▼ Sell | Open Market | 3,281 | $770K | 5/15/2024 | View on chart |
| STE | ▼ Sell | Open Market | 17,500 | $4.1M | 5/15/2024 | View on chart |
| STE | ▼ Sell | Open Market | 6,180 | $1.5M | 5/15/2024 | View on chart |
| STE | ▼ Sell | Tax Withholding | 830 | $166K | 5/31/2023 | View on chart |
| STE | ▲ Buy | Grant | 3,879 | $0 | 5/31/2023 | View on chart |
| STE | ▲ Buy | Grant | 2,256 | $0 | 6/2/2022 | View on chart |
| STE | ▼ Sell | Tax Withholding | 1,285 | $293K | 5/31/2022 | View on chart |
| STE | ▼ Sell | Open Market | 8,000 | $2.0M | 4/7/2022 | View on chart |
| STE | ▼ Sell | Open Market | 30,000 | $7.2M | 12/23/2021 | View on chart |
| STE | ▲ Buy | Option Exercise | 30,000 | $2.1M | 12/23/2021 | View on chart |
| STE | ▼ Sell | Open Market | 20,000 | $4.7M | 10/22/2021 | View on chart |
| STE | ▲ Buy | Option Exercise | 20,000 | $1.4M | 10/22/2021 | View on chart |
| STE | ▲ Buy | Grant | 576 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate
Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate. Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.